Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $4,525,301.06 in Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 147,934 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06. Following the completion of the transaction, the insider directly owned 169,753 shares in the company, valued at approximately $5,192,744.27. This trade represents a 46.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total value of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total value of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total value of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.
• On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Price Performance

Alamar Biosciences stock opened at $34.04 on Friday. The business’s 50 day moving average price is $30.73. Alamar Biosciences, Inc. has a fifty-two week low of $18.84 and a fifty-two week high of $39.61. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.23 and a current ratio of 11.85.

Alamar Biosciences (NASDAQ:ALMR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $29.43 million for the quarter. Equities research analysts predict that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Alamar Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. lifted its position in Alamar Biosciences by 18.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after acquiring an additional 10,461 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Alamar Biosciences during the 3rd quarter worth about $196,000. State Street Corp bought a new position in Alamar Biosciences during the 2nd quarter worth about $3,930,000. Squarepoint Ops LLC acquired a new stake in shares of Alamar Biosciences in the 2nd quarter valued at about $283,000. Finally, Braidwell LP acquired a new stake in shares of Alamar Biosciences in the 2nd quarter valued at about $29,365,000.

Analysts Set New Price Targets

A number of research firms recently commented on ALMR. TD Cowen restated a “buy” rating on shares of Alamar Biosciences in a research report on Wednesday, July 15th. Weiss Ratings lowered Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Stifel Nicolaus boosted their target price on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their price target on Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alamar Biosciences currently has an average rating of “Hold” and an average price target of $31.80.

Alamar Biosciences News Summary

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Strong ALS study validates Alamar’s technology. Emory researchers reported that a 10-protein blood signature detected ALS with 98.3% accuracy and outperformed a leading individual biomarker, including in difficult-to-diagnose cases. Publication in Nature Communications could improve the visibility and commercial credibility of Alamar’s NULISA proteomics platform. Alamar Biosciences’ Protein Signature Detects ALS With 98.3% Accuracy in Study
• Neutral Sentiment: Analyst views remain mixed. Earlier upgrades from Stifel and JPMorgan set price targets of $32 and $35, respectively, while Weiss Ratings downgraded the stock to sell. The broader analyst consensus is “Hold,” with an average target of $31.80, below the company’s recent trading range. Alamar remains unprofitable, although its latest quarterly loss was narrower than expected and revenue totaled $29.43 million.
• Negative Sentiment: Major shareholder Qiming continued a substantial selling program. Corporate GP VI Ltd. Qiming sold 100,837 shares on October 28 and 84,894 shares on October 27, following additional sales on October 26 and earlier dates. Across the reported transactions from October 15 through October 28, the shareholder sold approximately 1.2 million shares, reducing its position to 164,191 shares. The repeated insider-related selling may weigh on sentiment and suggests a significant near-term supply overhang. Alamar Biosciences SEC Insider Sale Filing

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.